Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin vs Daclizumab Induction in Positive Crossmatch Kidney Transplant
NCT00275509Phase 3Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2007
- Primary completion
- Jun 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of antithymocyte globulin in kidney transplant rejection (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Acute Cellular-mediated Rejection Rate (CMR) at 6 months, Acute Antibody-mediated Rejection Rate (AMR) at 6 months and 1 more. Started Jan 2007; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00275509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275509.